Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

@article{Motzer2010Phase3T,
  title={Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.},
  author={Robert J Motzer and Bernard Escudier and Stephane Oudard and Thomas E. Hutson and Camillo Porta and Sergio Bracarda and Viktor Gr{\"u}nwald and John A. Thompson and Robert Alan Figlin and Norbert Holl{\"a}nder and Andrea Kay and Alain Mure Ravaud},
  journal={Cancer},
  year={2010},
  volume={116 18},
  pages={4256-65}
}
BACKGROUND A phase 3 trial demonstrated superiority at interim analysis for everolimus over placebo in patients with metastatic renal cell carcinoma (mRCC) progressing on vascular endothelial growth factor receptor-tyrosine kinase inhibitors. Final results and analysis of prognostic factors are reported. METHODS Patients with mRCC (N = 416) were randomized (2:1) to everolimus 10 mg/d (n = 277) or placebo (n = 139) plus best supportive care. Progression-free survival (PFS) and safety were… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS